A phase 1 trial of the HDAC inhibitor AR-42 in patients with multiple myeloma and T- and B-cell lymphomas

Histone deacetylase inhibitors (HDACi) have proven activity in hematologic malignancies, and their FDA approval in multiple myeloma (MM) and T-cell lymphoma highlights the need for further development of this drug class. We investigated AR-42, an oral pan-HDACi, in a first-in-man phase 1 dose escala...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Leuk Lymphoma
Autors principals: Sborov, Douglas W., Canella, Alessandro, Hade, Erinn M., Mo, Xiaokui, Khountham, Soun, Wang, Jiang, Ni, Wenjun, Poi, Ming, Coss, Christopher, Liu, Zhongfa, Phelps, Mitch A., Mortazavi, Amir, Andritsos, Leslie, Baiocchi, Robert A., Christian, Beth A, Benson, Don M., Flynn, Joseph, Porcu, Pierluigi, Byrd, John C., Pichiorri, Flavia, Hofmeister, Craig C.
Format: Artigo
Idioma:Inglês
Publicat: 2017
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5489371/
https://ncbi.nlm.nih.gov/pubmed/28270022
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/10428194.2017.1298751
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars